553 related articles for article (PubMed ID: 19570025)
1. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.
Greggio E; Cookson MR
ASN Neuro; 2009 Apr; 1(1):. PubMed ID: 19570025
[TBL] [Abstract][Full Text] [Related]
2. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.
Xiong Y; Dawson VL; Dawson TM
Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868
[TBL] [Abstract][Full Text] [Related]
3. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
Greggio E
Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865
[TBL] [Abstract][Full Text] [Related]
4. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites.
Greggio E; Taymans JM; Zhen EY; Ryder J; Vancraenenbroeck R; Beilina A; Sun P; Deng J; Jaffe H; Baekelandt V; Merchant K; Cookson MR
Biochem Biophys Res Commun; 2009 Nov; 389(3):449-54. PubMed ID: 19733152
[TBL] [Abstract][Full Text] [Related]
5. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
[TBL] [Abstract][Full Text] [Related]
6. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.
West AB; Moore DJ; Choi C; Andrabi SA; Li X; Dikeman D; Biskup S; Zhang Z; Lim KL; Dawson VL; Dawson TM
Hum Mol Genet; 2007 Jan; 16(2):223-32. PubMed ID: 17200152
[TBL] [Abstract][Full Text] [Related]
7. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.
Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ
PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216
[TBL] [Abstract][Full Text] [Related]
8. LRRK2 in Parkinson's disease: protein domains and functional insights.
Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
Seol W
BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607
[TBL] [Abstract][Full Text] [Related]
10. The biology and pathobiology of LRRK2: implications for Parkinson's disease.
Moore DJ
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S92-8. PubMed ID: 18602856
[TBL] [Abstract][Full Text] [Related]
11. Contribution of GTPase activity to LRRK2-associated Parkinson disease.
Tsika E; Moore DJ
Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585
[TBL] [Abstract][Full Text] [Related]
12. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
Gandhi PN; Chen SG; Wilson-Delfosse AL
J Neurosci Res; 2009 May; 87(6):1283-95. PubMed ID: 19025767
[TBL] [Abstract][Full Text] [Related]
13. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
[TBL] [Abstract][Full Text] [Related]
14. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.
Cookson MR
Nat Rev Neurosci; 2010 Dec; 11(12):791-7. PubMed ID: 21088684
[TBL] [Abstract][Full Text] [Related]
15. Measuring the activity of leucine-rich repeat kinase 2: a kinase involved in Parkinson's disease.
Lee BD; Li X; Dawson TM; Dawson VL
Methods Mol Biol; 2012; 795():45-54. PubMed ID: 21960214
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.
Rudenko IN; Cookson MR
Neurotherapeutics; 2014 Oct; 11(4):738-50. PubMed ID: 24957201
[TBL] [Abstract][Full Text] [Related]
17. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.
Biosa A; Trancikova A; Civiero L; Glauser L; Bubacco L; Greggio E; Moore DJ
Hum Mol Genet; 2013 Mar; 22(6):1140-56. PubMed ID: 23241358
[TBL] [Abstract][Full Text] [Related]
18. Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease.
Gómez-Suaga P; Fdez E; Fernández B; Martínez-Salvador M; Blanca Ramírez M; Madero-Pérez J; Rivero-Ríos P; Fuentes JM; Hilfiker S
Neuropharmacology; 2014 Oct; 85():45-56. PubMed ID: 24863040
[TBL] [Abstract][Full Text] [Related]
19. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.
Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR
Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 pathobiology in Parkinson's disease.
Martin I; Kim JW; Dawson VL; Dawson TM
J Neurochem; 2014 Dec; 131(5):554-65. PubMed ID: 25251388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]